Dr Anthony Cunliffe, Lead Medical Adviser, Macmillan Cancer Support
Gunnar Philipp, Head of Medical Affairs Europe Major Markets & Canada, CSL Behring
PATIENTS & DECISION-MAKING
09.10 Proactive & Practical Patient Empowerment Strategies Which Enable Patients To Actively Drive Their Healthcare Journeys & Make Informed Decisions
Patients who actively participate in decision making have better health outcomes and satisfaction, so how can we empower patients to take a more active role in their healthcare decisions, especially in complex or life-changing situations?
How can we help HCPs better support patients in understanding their treatment options and explore the shift towards shared decision-making and what it means for both patients and clinicians?
How do we create an environment where patients feel capable and confident in making decisions which align with their needs, values and goals?
Debra Montague, Founder & Chairwoman, ALK Positive Lung Cancer UK
DOUBLE PERSPECTIVE
PATIENT ADVOCACY COMMUNICATION & COLLABORATION
09.30 Build Long-Lasting Trust & Enhance Relationships Between Pharma, Healthcare Providers, Patients & Advocates For Mutually-Beneficial Partnerships That Drive Engagement & Improve Outcomes
Effective communication between pharma, healthcare providers, and patient advocates is essential for improving patient care, but how can it be achieved?
Explore innovative ways pharma companies can collaborate with patient groups to build trust and ensure accurate information flow
Poor communication can lead to confusion, mistrust, and missed opportunities to improve patient outcomes, so how can pharma better support patient advocacy groups and help them amplify their voices in healthcare discussions?
09.30 Perspective 1
Phillip Ho, Global Vaccines Public Affairs, Sanofi Pasteur
Vinny Smith, Chief Executive, Meningitis Research Foundation
09.50 Perspective 2
Mary Lynne van Poelgeest-Pomfret, President, WFIPP
PANEL Q&A
PATIENT REPRESENTATION & INCLUSION IN CLINICAL TRIALS
Explore brand new strategies to improve diversity in clinical trials, considering all factors from age, ethnicity, and socioeconomic in order to truly reflect diverse experiences
Embed the patient voice in trial design processes to ensure their needs and requirements are integrated into trials from the very start
From access issues to biases, pinpoint exactly what’s preventing true inclusivity in clinical trials, and how we can overcome these challenges in 2025 and beyond
Hear first-hand how patient groups are working alongside pharma companies to address disparities and create trial designs which include and benefit everyone
John Ioannou, VP, Global Medical Head of Immunology Therapeutic Area, UCB
Anisha Lad, Senior Medical Affairs Advisor – Oncology, Pfizer
Sumair Nizamuddin, Paediatric Impact & Engagement Manager, Experimental Cancer Medicine Centres, Cancer Research UK
11.25 Bonus Session; Reserved For Exclusive Conference Partner
INTERACTIVE DELEGATE DISCUSSION
AI, NEW TECH & INNOVATION IN HEALTHCARE
11.40 Utilise AI & New, Innovative Technologies To Improve Patient Care – Compliantly – Without Losing The Critical Human Touch
AI, AI, AI, it’s everywhere we know, but is it really possible for AI and new tech to enhance patient care while maintaining an authentic personal touch?
How can we evidence systems are reliable and beneficial to build patient trust in new tech and AI to ensure they are interacting with value-add services
Industry benchmarking: what role will AI and digital technologies play in the future of patient care?
Explore the new opportunities and challenges which come alongside integrating AI into diagnostics, treatment, and patient management
PANEL Q&A HEAR FROM THE PATIENTS THEMSELVES
PATIENT PERSPECTIVES IN TREATMENT – QUALITY OF LIFE
12.00 Prioritise Quality Of Life In Treatment Decisions For All Patients By Building Holistic Healthcare Systems Around Patient Needs & Expectations
What do patients really want, and expect, from Pharma to advance advocacy objectives and truly improve holistic patient quality of life in 2025 and beyond?
As life expectancy increases, older populations are increasingly focused on quality of life rather than just longevity, so how can healthcare systems respond appropriately to this shift?
There’s a growing need for holistic care that considers both physical and mental health, beyond just prolonging life. How can we address the emotional and cognitive effects of chronic conditions while ensuring patients still receive effective care?
Mary Lynne van Poelgeest-Pomfret, President, WFIPP
Juddy Otti, GROWS Lead, Sophia Forum UK
BARRIERS TO PATIENT CENTRICITY
12.30 Overcome Persistent Internal & External Barriers To Patient Centricity To Achieve Real Change & Ensure All Teams Are Moving In The Same Direction
Despite the push for patient-centric care, many organisations still face significant internal and external barriers to true engagement. Discover new, proven and successful strategies to overcome these barriers and foster true patient-centric cultures
How can companies integrate patient feedback throughout the entire healthcare process, from clinical trials to treatment?
Explore how organisational processes, compliance issues, and resource gaps can prevent effective patient involvement in order to mitigate barriers and areas of resistance
Ravindra Deore, Senior Medical Director, Global Medical Affairs, Mundipharma
PANEL Q&A
PATIENT INVOLVEMENT IN HTA
12.50 Champion PAGs & Amplify Patient Voices In Health Technology Assessments For More Equitable Healthcare Decisions
What are the most effective ways to involve patients in HTA and how can we quantify that positive impact on equitable healthcare policies and real-world patient needs?
What are the barriers preventing effective patient involvement in HTAs, and how can we overcome them? Hear about the positive outcomes when patient representatives successfully influence HTA decisions in Europe and beyond
How can patient representatives impact HTA processes to ensure that treatments are evaluated from the patient’s perspective?
Matthijs van Meerveld, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline
13.20 Lunch & Informal Networking For Speakers, Delegates & Partners
OPENING REMARKS
14.20 Afternoon Co-Chairs’ Opening Remarks
Dr Rick Lones, VP, Global Head of Medical Affairs, Mundipharma
Pam Jayia, Associate Group Medical Director, Clinical Safety, Roche
PANEL Q&A
STAKEHOLDER COLLABORATION
14.30 Break Down Siloes To Increase Multi-Stakeholder Collaboration, Better Respond To Patient Needs & Improve Outcomes
Pharmaceutical companies, healthcare providers and patient groups often work in silos but how can we unite complex stakeholder networks across healthcare to align behind goals and improve patient care?
Uncover how organisations are already bridging gaps between stakeholders to improve communication and transparency – compliantly
What role can pharma play in supporting patient groups’ advocacy and operational capacity to achieve better patient outcomes, faster treatment access and more personalised care?
Mary Lynne van Poelgeest-Pomfret, President,WFIPP
Melanie Costin, Interim Chief Executive Officer, Fight Bladder Cancer
PATIENT ADVOCACY COMMUNICATION & COLLABORATION
15.00 Build Long-Lasting Trust & Enhance Relationships Between Pharma, Healthcare Providers, Patients & Advocates For Mutually-Beneficial Partnerships That Drive Engagement & Improve Outcomes
Effective communication between pharma, healthcare providers, and patient advocates is essential for improving patient care, but how can it be achieved?
Explore innovative ways pharma companies can collaborate with patient groups to build trust and ensure accurate information flow
Poor communication can lead to confusion, mistrust, and missed opportunities to improve patient outcomes, so how can pharma better support patient advocacy groups and help them amplify their voices in healthcare discussions?
Emily Burns, Patient Advocacy Lead, AstraZeneca UK
CASE STUDY
PATIENT TRUST WITH HEALTH SYSTEMS
15.20 Exclusive Case Study Around Patient Trust With Health Systems
Looking into patients trust in data sharing and the barriers with patients out for diagnosis and treatment
Deep dive into the reasons and factors involving why patients have trust issues with health systems which lead to a lack of engagementRecommendations on what can be done to improve these challenges
Sumair Nizamuddin, Paediatric Impact & Engagement Manager, Experimental Cancer Medicine Centres, Cancer Research UK
15.40 Bonus Session; Reserved For Exclusive Conference Partner
16.40 Power End-To-End Patient Engagement By Truly Listening, Authentically Valuing & Effectively Responding To Diverse Patient Needs
Patient engagement increases when patients feel heard, valued, and understood, so how can we truly listen and respond to their needs?
Integrating the patient voice in all stages of the healthcare journey is crucial, so how can organisations ensure they are engaging patients authentically, while remaining sensitive to their diverse experiences and challenges?
Uncover new insights from organisations that have successfully put the patient voice at the centre of their work, demonstrably improving outcomes for all
16.40 Perspective 1
Jannike Nordlund, Programme Manager for Patient Involvement, Experience & Inequalities, South East London Cancer Alliance
17.00 Perspective 2
Lili White, Senior Communications & Campaigns Officer, MS International Federation
DIAGNOSTICS & BRAIN HEALTH - FIRESIDE CHAT
17.20 Exclusive Session With Roche Diagnostics Ltd
Ashton Harper, MD, Head of Medical Affairs (UK & Ireland), Roche Diagnostics Ltd
PROMOTING PATIENT AUTONOMY – COLLABORATING ON PERSONALISED TREATMENT PLANS
17.40 Empower Patients & Prioritise Patient Autonomy By Designing & Implementing Personalised Treatment Plans For Better Health Outcomes
Empowering patients to make informed decisions can lead to better health outcomes and improved patient satisfaction, so how can clinicians, pharma, and patients work together to create personalised cared plans?
Explore the importance of personalised treatment plans and the barriers patients face when trying to access innovative therapies
How can we help patients take ownership of their treatment decisions when new, adaptive therapies become available?
Helen Bulbeck, Director of Services & Policy, brainstrust
18.00 Afternoon Co-Chairs’ Closing Remarks & Close Of Conference
Dr Rick Lones, VP, Global Head of Medical Affairs, Mundipharma
Pam Jayia, Associate Group Medical Director, Clinical Safety, Roche
Please check the Patient Centricity & Engagement Conference website regularly for programme updates and confirmed speakers. For more information or to get involved, please call 44 (0)20 3479 2299 or email info@patientengagementconference.com